pharma.markets

pharma.markets

  • HOME
  • Imprint

Cancer

Novartis Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrates unprecedented efficacy in pediatric patients with BRAF V600 low-grade gliomas in Phase II/III study

06/06/2022 MaP 0

Treatment with targeted therapies Tafinlar + Mekinist resulted in 47% ORR versus chemotherapy (11%) and reduced risk of progression or death by 69%, showing significant […]

European Stroke Organisation Conference 2022: New study links gut microbiota strains with more severe strokes and poorer post-stroke recovery

04/05/2022 MaP 0

A new study has identified strains of gut microbiota that are associated with more severe strokes and worse post-stroke recovery, revealing that the gut microbiome […]

New imaging method reveals causes of cerebral oedema

31/01/2022 MaP 0

Neurobiology: Publication in the Journal for Neuroscience Cerebral oedema is a dangerous complication in many brain-related conditions such as strokes. Researchers at the Institute of […]

BioNTech and Crescendo Biologics Announce Global Collaboration to Develop Multi-specific Precision Immunotherapies

10/01/2022 MaP 0

Collaboration leverages BioNTech’s proprietary multimodal immunotherapy expertise with Crescendo’s proprietary Humabody® VH platform to develop precision immunotherapies, including mRNA-based antibodies and engineered cell therapies against […]

Alligator Bioscience Announces Trial Update and Early Readout for ATOR-1017 Confirming Biomarker, Safety & Tolerability Data

18/12/2021 MaP 0

Alligator Bioscience (Nasdaq Stockholm: ATORX) today announced an update on the on-going clinical Phase I trial with the 4-1BB (CD137) drug candidate ATOR-1017, which is […]

Spoiled oranges shine light on malignant cells

14/12/2021 MaP 0

Biomedical device passes the litmus test A University of Sydney PhD researcher is developing a cancer and serious disease-detecting biomedical probe that can be made […]

Novartis Kymriah® demonstrates strong responses in high-risk patients with relapsed or refractory follicular lymphoma in extended study follow-up

12/12/2021 MaP 0

Complete and overall response rates and durability of response were well maintained across majority of high-risk subgroups with a significant unmet need1 Median follow-up of […]

Novartis Scemblix® demonstrates sustained response rate in 48-week follow-up in patients with chronic myeloid leukemia

12/12/2021 MaP 0

Updated 48-week data from Phase III ASCEMBL trial consistent with improved major molecular response (MMR) rate of Scemblix® (asciminib) vs. Bosulif®* (bosutinib) and lower discontinuation […]

Biocytogen/Eucure Biopharma Announce the Completion of First Patient Dosing for Phase I Clinical Trial of YH004 (Anti-4-1BB Monoclonal Antibody) in Australia

09/12/2021 MaP 0

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I clinical trial of YH004 (anti-4-1BB monoclonal antibody, mAb) (No. […]

New Kisqali® data shows consistent overall survival benefit across genomic and clinical subtypes of interest in HR+/HER2- metastatic breast cancer

09/12/2021 MaP 0

Data from the MONALEESA Phase III program provide further evidence of the unique profile of Kisqali, the CDK4/6 inhibitor with the longest reported median overall […]

PharmaMar Group reports 9 month 2021 financial results

02/11/2021 MaP 0

The Group’s recurring revenues (sales plus royalties) grew by 31% to €119 million during the first 9 months. Total revenues amounted to €144 million. The […]

BioNTech to Acquire Kite’s Neoantigen TCR Cell Therapy R&D Platform and Manufacturing Facility in Gaithersburg, MD

19/07/2021 MaP 0

BioNTech SE (Nasdaq: BNTX, “BioNTech”) and Kite, a Gilead Company (Nasdaq: GILD, “Kite”) today announced the two companies have entered into a purchase agreement for […]

Messenger RNA in covid-19 vaccines could open doors to cancer treatment

21/04/2021 MaP 0

The technology used in some Covid-19 doses could facilitate different vaccines or treatments for certain cancers. These advances need the firm and constant support of […]

Pivotal Phase III study shows Roche’s Tecentriq helped people with early lung cancer live longer without their disease returning

22/03/2021 MaP 0

First Phase III study to show that a cancer immunotherapy improves disease-free survival in people with resectable early stage lung cancer compared to best supportive […]

Merck Announces Leadership Change for North America and Global Innovative Medicine Franchises in Healthcare

05/02/2021 MaP 0

Merck today announced that Rehan Verjee has made the decision to leave his position as President of EMD Serono and Global Head of Innovative Medicine […]

Posts navigation

1 2 3 »

Translation

en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianja Japaneseko Koreanpt Portugueseru Russianes Spanish

Search

Categories

  • Age.related Degeneration
  • Alzheimer
  • Animal health
  • Asthma
  • Bioscience
  • Cancer
  • Conferences
  • COVID-19
  • EIB
  • EU
  • FCPA Investigations
  • FDA
  • Finance
  • Food
  • HHS
  • Humanitarian Aid
  • Imprint
  • Influenza
  • Innovation
  • Mental Health
  • MS
  • News
  • Research
  • Rheumatology
  • Space Science
  • Spain
  • Sports
  • Therapy
  • Trade Fair
  • UN
  • Vaccines
  • Valencia Comunidad
  • WHO

Reports

  • Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®
  • Merck has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform
  • Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY®
  • Pfizer and BioNTech Submit a Variation to EMA
  • Statement on Patent Infringement Lawsuit in Germany

Archive

  • August 2022 (2)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
  • Novaliq submits New Drug Application seeking approval for first-of-a-kind Dry Eye Disease Treatment CyclASol®

    09/08/2022 0
  • Merck has launched the VirusExpress® 293 Adeno-Associated Virus (AAV) Production Platform

    09/08/2022 0
  • Pfizer and BioNTech Announce U.S. FDA Approval of their COVID-19 Vaccine COMIRNATY®

    08/07/2022 0
  • Pfizer and BioNTech Submit a Variation to EMA

    08/07/2022 0
  • Statement on Patent Infringement Lawsuit in Germany

    05/07/2022 0
Archives
  • August 2022 (2)
  • July 2022 (3)
  • June 2022 (8)
  • May 2022 (1)
  • April 2022 (2)
  • March 2022 (5)
  • February 2022 (9)
  • January 2022 (19)
  • December 2021 (37)
  • November 2021 (17)
  • October 2021 (5)
  • August 2021 (5)
  • July 2021 (5)
  • June 2021 (1)
  • May 2021 (6)
  • April 2021 (9)
  • March 2021 (23)
  • February 2021 (22)
  • January 2021 (11)
  • December 2020 (29)
  • November 2020 (7)
  • October 2020 (6)
  • September 2020 (17)
  • August 2020 (1)
  • July 2020 (4)
  • June 2020 (99)
  • May 2020 (201)
  • April 2020 (269)
  • March 2020 (29)
TAGS
affected africa aid biontech cancer commission companies coronavirus covid-19 covid19 data economy elpais.com emergency eu europe european fda food global guarantee health hygiene links medical merck novartis pandemic pfizer production recommendations region response roche safety scheme sector spain state statistics support us vaccine vaccines who

Copyright © 2022 | WordPress Theme by MH Themes

Cookie Consent with Real Cookie Banner